참고문헌
- Blaser MJ. Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology 1987;93:371-383.
- Correa P, Piazuelo MB. Natural history of Helicobacter pylori infection. Dig Liver Dis 2008;40:490-496. https://doi.org/10.1016/j.dld.2008.02.035
- Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 2010;25:479-486. https://doi.org/10.1111/j.1440-1746.2009.06188.x
- Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994;89(suppl 8):116S-1128S.
- Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008;13(suppl 1):35S-40S.
- Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37. https://doi.org/10.1038/nrc703
- Sherman PM. Appropriate strategies for testing and treating Helicobacter pylori in children: when and how? Am J Med 2004;117(suppl 5A):30S-35S.
- Malfertheiner P, Meegraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
- Asaka M, Satoh K, Sugano K, et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001;6:177-186. https://doi.org/10.1046/j.1523-5378.2001.00027.x
- Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. https://doi.org/10.1136/gut.2006.101634
- Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-1600. https://doi.org/10.1111/j.1440-1746.2009.05982.x
- Kim BW, Choi MG, Moon SB, et al. Pooled analysis of antibiotic therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 1999;34:42-49.
- Lee KH, Kim NY, Ko YH, el al. Triple therapy for eradication of H. pylori in patients with peptic ulcer. Korean J Gastroenterol 1998;31:605-614.
- Lee KM, Lee DS, Ahn BM, et al. Effect of one-week triple therapy of ranitidine bismuth citrate, amoxicillin and clarithromycin in Helicobacter pylori-related peptic ulcer patients. Korean J Gastroenterol 2001;37:412-417.
- Chung WC, Cho YS, Jeong JJ, et al. Eradication rate of Helicobacter pylori according to the diseases and therapeutic regimens, and reinfection rate after successful eradication in a tertiary clinic. Korean J Gastroenterol 2003;41:1-8.
- Choi YS, Cheon JH, Lee JY, et al. The trend of eradicatin rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol 2006;48:156-161.
- Nam TM, Lee DH, Kang KP, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc 2008;36:200-205.
- Broutet N, Tchamgouee S, Pereira E, at al. Risk factors for failure of Helicobacter pylori therapy: results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109. https://doi.org/10.1046/j.1365-2036.2003.01396.x
- Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136:13-24. https://doi.org/10.7326/0003-4819-136-1-200201010-00008
- Meegraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384. https://doi.org/10.1136/gut.2003.022111
- Onoda Y, Magaribuchi T, Tamaki H. Effects of the new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats. Arzneimittelforschung 1990;40:576-578.
- Ito Y, Onoda Y, Nakamura S, et al. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein. Jpn J Pharmacol 1993;62:175-181. https://doi.org/10.1254/jjp.62.175
- Ito Y, Shibata K, Hongo A, Kinoshita M. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol 1998;345:193-198. https://doi.org/10.1016/S0014-2999(97)01622-1
- Shibata K, Ito Y, Hongo A, Yasoshima A, Endo T, Ohashi M. Bactericidal activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori Under acidic conditions. Antimicrob Agents Chemother 1995;39:1295-1299. https://doi.org/10.1128/AAC.39.6.1295
- Shibata K, Kasuga O, Yasoshima A, Matsushita T, Kawakami Y. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. Jpn J Antibiot 1997;50:525-531.
- Adachi K, Ishihara S, Hashimoto T, et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther 2001;15:1187-1191. https://doi.org/10.1046/j.1365-2036.2001.01022.x
- Kim H, Kim GH, Cheoug JY, et al. H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008;14:908-912. https://doi.org/10.3748/wjg.14.908
- Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;14:5385-5402. https://doi.org/10.3748/wjg.14.5385
- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153. https://doi.org/10.1136/gut.2009.192757
- Kim JM, Kim JS, Jung HC, et al. The effects of ecabet sodium on nuclear factor-kappa B activation and chemokine gene expression in Helicobacter pylori-infected human gastric epitherlial cells. Korean J Med 2003;65:178-187.
- Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol 2006;47:337-349.
- Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006;40:683-687. https://doi.org/10.1097/00004836-200609000-00004
- Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-4010. https://doi.org/10.1128/JCM.00740-07
- Glupczynski Y, Meegraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-823. https://doi.org/10.1007/s100960100611
- Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010;15:460-466. https://doi.org/10.1111/j.1523-5378.2010.00788.x
- Chuang CH, Sheu BS, Kao AW, et al. Adjuvant effect of vitamin C on omeprazole-amoxicillin-clarithromycin triple therapy for Helicobacter pylori eradication. Hepatogastroenterology 2007;54:320-324.
- De Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007;102:951-956. https://doi.org/10.1111/j.1572-0241.2007.01085.x